The Asia Pacific Biodefense Market is expected to witness market growth of 7% CAGR during the forecast period (2020-2026).
Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.
The advancements in technology have encouraged the innovation of advanced biosensor technology that is able to check both pathogens and benign microorganisms. In addition, various agencies are striving to create multifunctional sensors. Biotechnology provides an opportunity for the development of efficient countermeasures to biological weapons. Development and manufacturing of vaccines are of utmost importance from a biosecurity outlook.
The biodefense market will witness developmental possibilities if the government undertakes constant preventive steps to ensure the safety of the population and the economy. As the governments invest in these current and future policy initiatives, the companies operating in the market will witness a significant push in their revenue streams, by understanding the existing biosecurity and biodefense policy.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
By Country
Companies Profiled
Unique Offerings from the Publisher
Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.
The advancements in technology have encouraged the innovation of advanced biosensor technology that is able to check both pathogens and benign microorganisms. In addition, various agencies are striving to create multifunctional sensors. Biotechnology provides an opportunity for the development of efficient countermeasures to biological weapons. Development and manufacturing of vaccines are of utmost importance from a biosecurity outlook.
The biodefense market will witness developmental possibilities if the government undertakes constant preventive steps to ensure the safety of the population and the economy. As the governments invest in these current and future policy initiatives, the companies operating in the market will witness a significant push in their revenue streams, by understanding the existing biosecurity and biodefense policy.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segmentation:
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/nuclear,
- Other Products
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Biodefense Market by Product
Chapter 5. Asia Pacific Biodefense Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Methodology
LOADING...
